Call Us: +44 (0) 1752 753723[email protected]


Madrid, Oct 24 (Prensa Latina) Spanish medical institutions announced the beginning of a pioneering clinical test to eradicate the Human Immunodeficiency Virus (HIV) with a genetic mutation of blood from the umbilical cord, known as CCR5 Delta 32.

According to the specialized publication Doctors and Patients, it is a previous case before the first clinical trial of its kind in the world which they trust to start between next December and January at the Hospital Puerta de Hierro-Majadahonda of Madrid

The journal says the director of the National Transplants Organization (NTO), Rafael Matesanz, confirmed recently that it is about using a genetic cell mutation of blood stem cells of very low prevalence among Spaniards.

Matezans said the cords CCR5 Delta32 are an authentic peculiarity, as the experts calculated it is present only in one percent of the world population, but in Spain, its prevalence is 0.6 percent.

The senior researcher of the Project, Rafael Duarte, explained that the test is based on the elimination of HIV in a patient in 2013 in Barcelona, through a transplant of blood from a cord with that genetic variant, made for the first time in the world.

The objective is to validate the experience of the patient of Barcelona, understand the factors that determine the healing and generate the first scientific evidence on the therapeutic use of the blood of cord CCR5 Delta32, explained Duarte.

This test will be carried out in five adult patients with infection HIV and indication of blood stem cells transplant allogeneic for suffering from leukaemia, lymphoma or another neoplasia of the blood and lacking a family donor.

Participants will have a clinical follow-up and lab tests done post-transplant for a minimum of 12 months.

To read the full article click here.